{
    "paper_id": "PMC7163933",
    "metadata": {
        "title": "Computational Design of ACE2-Based Peptide Inhibitors of\nSARS-CoV-2",
        "authors": [
            {
                "first": "Yanxiao",
                "middle": [],
                "last": "Han",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Petr",
                "middle": [],
                "last": "Kr\u00e1l",
                "suffix": "",
                "email": null,
                "affiliation": {}
            }
        ]
    },
    "body_text": [
        {
            "text": "In the crystal structure of ACE2 and RBD of SARS-CoV-2 (PDB: 6M17(9)), we first analyzed the interacting amino acids at\nthe ACE2 and RBD interface. In total, 15 residues from ACE2 interact\nwith RBD: residues 24(Q), 27(T), 30(D), 31(K), 34(H), 35(E), 37(E),\n38(D), 41(Y), and 42(Q) are in \u03b11, one residue\n(residue 82 M) comes from \u03b12, residues 353(K),\n354(G), 355(D), and 357(R) come from the linker between\n\u03b23 and \u03b24. Therefore, the 15\namino acids can be labeled as critical amino acids and\n\u03b11, \u03b12, \u03b23,\nand \u03b24 as critical binding components.",
            "cite_spans": [
                {
                    "start": 66,
                    "end": 67,
                    "mention": "9",
                    "ref_id": "BIBREF20"
                }
            ],
            "section": "Preparation of Inhibitors ::: Results and Discussion",
            "ref_spans": []
        },
        {
            "text": "Because most of the interacting residues are from \u03b11, we\npicked as inhibitor 1 the \u03b11-helix\nalone. In particular, the 21\u201355 residues, shown in Figure 1a, were selected.\nRealizing that \u03b11 (alone) might not even be stable,\nwe next picked as inhibitor 2 both \u03b11-\nand \u03b12-helices (residues 21 to 88) and the residues\n349 to 357 (residues between \u03b23 and\n\u03b24 shown in orange in Figure\n1b). This selection included all\n15 interacting residues from the crystal structure 6M17.9 As the two \u03b1-helices are closely joined on\none side (Figure 1b), they\nstabilize each other. To connect the two helices (red) with the\n\u03b2-sheets with residues 349 to 357 (orange), as shown in Figure 1b, residues 45 (LEU)\nand 351 (LEU) were linked together by a side chain with a\ncarbon\u2013carbon bond, as shown in Figure 2b.",
            "cite_spans": [
                {
                    "start": 466,
                    "end": 467,
                    "mention": "9",
                    "ref_id": "BIBREF20"
                }
            ],
            "section": "Preparation of Inhibitors ::: Results and Discussion",
            "ref_spans": [
                {
                    "start": 143,
                    "end": 151,
                    "mention": "Figure 1",
                    "ref_id": "FIGREF0"
                },
                {
                    "start": 370,
                    "end": 378,
                    "mention": "Figure\n1",
                    "ref_id": "FIGREF0"
                },
                {
                    "start": 521,
                    "end": 529,
                    "mention": "Figure 1",
                    "ref_id": "FIGREF0"
                },
                {
                    "start": 658,
                    "end": 666,
                    "mention": "Figure 1",
                    "ref_id": "FIGREF0"
                },
                {
                    "start": 777,
                    "end": 785,
                    "mention": "Figure 2",
                    "ref_id": "FIGREF1"
                }
            ]
        },
        {
            "text": "We have also designed other inhibitors that are closer to the ACE2\nprotein, whose parts are connected by peptide bonds, and which contain\nall 15 residues that initially bind to RBD in the 6M17 crystal\nstructure.9Figure 1c (detail in Figure 1e) shows inhibitor\n3, where residues 323 to 362 (orange) include the\ntwo \u03b2-sheets and a random coil (residues 323 to 348), whereas\nresidues 21 to 105 (red) include the two \u03b1-helices with another\nrandom coil (residues 89 to 105). The two sequences are joined\ntogether by a peptide bond between residues 105 and 323, and the two\npieces of random coils were moved close to each other. Finally, Figure 1d (detail in Figure 1f) shows inhibitor\n4, where two sequences including residues 21 to 95\n(red) and residues 335 to 500 (orange) were selected. An extra peptide\nbond was made between residue 21 and residue 400 by adjusting the\nposition of the corresponding sequences. The sequences of all\ninhibitors are shown in Table S1.",
            "cite_spans": [
                {
                    "start": 211,
                    "end": 212,
                    "mention": "9",
                    "ref_id": "BIBREF20"
                }
            ],
            "section": "Preparation of Inhibitors ::: Results and Discussion",
            "ref_spans": [
                {
                    "start": 212,
                    "end": 220,
                    "mention": "Figure 1",
                    "ref_id": "FIGREF0"
                },
                {
                    "start": 233,
                    "end": 241,
                    "mention": "Figure 1",
                    "ref_id": "FIGREF0"
                },
                {
                    "start": 632,
                    "end": 640,
                    "mention": "Figure 1",
                    "ref_id": "FIGREF0"
                },
                {
                    "start": 653,
                    "end": 661,
                    "mention": "Figure 1",
                    "ref_id": "FIGREF0"
                }
            ]
        },
        {
            "text": "To examine how these potential inhibitors bind to RBD of SARS-CoV-2, we\nprepared these systems in the initial position known from the crystal\nstructure (PDB: 6M17) and simulated them in physiological solution\n(Methods), as shown in Figure 2a\u2013d. As a control, the\nPD of ACE2 (residues 19 to 615) and RBD of SARS-CoV-2 were also\nsimulated (Figure 2e).",
            "cite_spans": [],
            "section": "Preparation of Inhibitors ::: Results and Discussion",
            "ref_spans": [
                {
                    "start": 232,
                    "end": 240,
                    "mention": "Figure 2",
                    "ref_id": "FIGREF1"
                },
                {
                    "start": 338,
                    "end": 346,
                    "mention": "Figure 2",
                    "ref_id": "FIGREF1"
                }
            ]
        },
        {
            "text": "In Figure 2a, 200 ns long\nsimulations showed that the helical structure of inhibitor\n1 deforms from the left side\u2014loose end\nunfolding, although it still binds to the RBD of SARS-CoV-2. In Figure 2b\u2013d,\n120\u2013300 ns long simulations revealed that inhibitors\n2\u20134 bind in a stable way to the\nRBD of SARS-CoV-2, without \u03b11 losing its structure.\nDue to different linkages among the critical binding components, the\noverall conformations of inhibitors\n2\u20134 vary. Specifically, the\n\u03b11-helix, which mostly contributes to the\ncomplementary sequence and conformational matching to RBD, is\nmaintained in inhibitors 2\u20134 with\ndifferent degrees of bending. The \u03b2-sheets in the structures of\ninhibitors 3 and 4 are also preserved.\nOverall, the critical binding components in inhibitors\n2\u20134 bind to RBD in a manner\nvery similar to that of the crystal structure. The simulated stable\nconformation of inhibitors 2, 3, and\n4 correspond to their energy minima of folding,\nwhich would drive the folding process toward the stable direction.",
            "cite_spans": [],
            "section": "Binding Conformations ::: Results and Discussion",
            "ref_spans": [
                {
                    "start": 3,
                    "end": 11,
                    "mention": "Figure 2",
                    "ref_id": "FIGREF1"
                },
                {
                    "start": 188,
                    "end": 196,
                    "mention": "Figure 2",
                    "ref_id": "FIGREF1"
                }
            ]
        },
        {
            "text": "To further quantify the binding of these inhibitors to RBD, we calculated\nthe RMSD for the 15 critical amino acids in each inhibitor and for the\nwhole inhibitors. Figure 2f\nshows the average RMSD at the end of our simulations (see also\nFigure S1). Inhibitor 1 has larger RMSD\nfor the critical amino acids compared to that of the control and the\nlargest fluctuations for both the critical amino acids and the overall\nRMSD (Figure S1a,b). This can be attributed to unfolding\nof \u03b11, shown in Figure 2a. A highly promising inhibitor\n2 has a RMSD of the critical amino acids and the\noverall RMSD similar to those in the control (lowest). Inhibitor\n3 has a RMSD of the critical amino acids and the\noverall RMSD higher than that of the control and inhibitors\n1 and 2. However, Figure S1b shows that inhibitor 3 has a\nvery smooth overall RMSD at later times. This may be due to a poor\nadaptation of their added connections at early times. Inhibitor\n4 shows slightly bigger fluctuation for the overall\nRMSD but steady RMSD (Figure S1a) for the critical amino acids at later\ntimes, which indicates fluctuation shown in the overall structure\ncomes from nonessential connection parts.",
            "cite_spans": [],
            "section": "Root-Mean-Square Deviation (RMSD) and Interaction Energies ::: Results and Discussion",
            "ref_spans": [
                {
                    "start": 163,
                    "end": 171,
                    "mention": "Figure 2",
                    "ref_id": "FIGREF1"
                },
                {
                    "start": 489,
                    "end": 497,
                    "mention": "Figure 2",
                    "ref_id": "FIGREF1"
                }
            ]
        },
        {
            "text": "The interaction energies have van der Waals (vdW) and electrostatic\ncomponents, calculated by the NAMD energy plugin. The total energies\nare shown in Figure 2 g and\nFigure S2 (detail). The residues which contribute to\nthe interaction energies between inhibitors and SARS-CoV-2 are\nselected with a cutoff of 3 \u00c5. The selections are updated in\nevery frame. Inhibitors 1 and 4 show\ninteraction energies similar to those of the control, with inhibitor\n3 having slightly stronger binding than the\ncontrol; however, inhibitor 2 shows an interaction energy\nslightly lower than that of the control. The larger interaction energy\nin inhibitor 1 might be due to nonspecific interactions\ncaused by the deformed helix. The lower interaction energy in\ninhibitor 2 could be attributed to the total number of\nresidues, which is less than those of inhibitor 3 and\n4.",
            "cite_spans": [],
            "section": "Root-Mean-Square Deviation (RMSD) and Interaction Energies ::: Results and Discussion",
            "ref_spans": [
                {
                    "start": 150,
                    "end": 158,
                    "mention": "Figure 2",
                    "ref_id": "FIGREF1"
                }
            ]
        },
        {
            "text": "In summary, using classical molecular dynamics simulations, we have shown that\npeptide inhibitors extracted from ACE2 provide highly promising trails for\nSARS-CoV-2 blocking. The single \u03b11-helix used in inhibitor\n1 is less stable, whereas the\n\u03b11,2-helices used in inhibitors\n2\u20134 support each other and retain\ntheir bent shape, which provides a conformational matching to the RBD of\nSARS-CoV-2 and a full cover of the RBD surface. Precise conformational\nmatching between the designed peptides and the virus provides room for\nimproving the binding affinity, which should be considered in future\ninhibitor design protocols. Suitable inhibitors should have a selective\nbinding with lower RMSD for critical amino acids and relatively high binding\nenergies. The binding affinity could be further enhanced by a multivalent\nbinding of multiple peptides attached to surfaces of nanoparticles,\ndendrimers, and clusters. In analogy to nanoparticle-based\ninhibitors,14 we could attach to the\n\u03b11 helix a sulphonated ligand mimicking a heparane\nsulfate, which can attach to positively charged residues at the bottom of\nRBD. These inhibitors could be used as inhaled therapeutics, preventing the\nvirus activation in lungs.",
            "cite_spans": [
                {
                    "start": 954,
                    "end": 956,
                    "mention": "14",
                    "ref_id": "BIBREF5"
                }
            ],
            "section": "Conclusions",
            "ref_spans": []
        },
        {
            "text": "The time-dependent RMSD for the critical amino acids and the whole\ninhibitors (Figure S1) were calculated\nfrom1where\nN\u03b1 is the number of atoms\nwhose positions are being compared,\nr\u20d7\u03b1(tj)\nis the position of atom \u03b1 at time\ntj, and\nr\u20d7\u03b1(t0)\nis the initial coordinate. The selection of coordinates contains all\nof the atoms in the inhibitors or critical amino acids, excluding\nhydrogens.",
            "cite_spans": [],
            "section": "Calculation of RMSD ::: Methods",
            "ref_spans": []
        },
        {
            "text": "The time-dependent RMSD was averaged over the last 50 ns of simulation\ntime, which corresponds to the last 50 frames of each trajectory, as\nshown in Figure 2f. The\nstandard deviations are shown by the error bars.",
            "cite_spans": [],
            "section": "Calculation of RMSD ::: Methods",
            "ref_spans": [
                {
                    "start": 149,
                    "end": 157,
                    "mention": "Figure 2",
                    "ref_id": "FIGREF1"
                }
            ]
        },
        {
            "text": "The interacting residues from inhibitors and RBD of SARS-CoV-2 were first\nselected with a 3 \u00c5 cutoff distance. The electrostatic and vdW\nenergy contributions between the interacting residues are calculated\nby the NAMD energy plugin. The electrostatic contribution is given\nby2where\n|r\u20d7i\n\u2013 r\u20d7j| is\nthe distance between the two charges,\nqi and\nqj; \u03b5 is the\ndielectric constant of the solvent which is set to 1. To increase the\nefficiency of the simulations, pairwise interaction calculations are\nnot performed beyond a cutoff distance. Long-range electrostatic\ninteractions are calculated by the PME method.21",
            "cite_spans": [
                {
                    "start": 605,
                    "end": 607,
                    "mention": "21",
                    "ref_id": "BIBREF13"
                }
            ],
            "section": "Calculation of Binding Energy ::: Methods",
            "ref_spans": []
        },
        {
            "text": "The Lennard-Jones (LJ) 6\u201312 potential energies are used to\ndescribe the vdW interactions and close distance atomic\nrepulsions:3where\n\u03b5ij is the maximum\nstabilization energy for the ith and the\njth atoms,\n\u03c3ij is the distance between\nith and jth atoms at the\nminimum of the potential, and\nrij is the\nactual distance between the two atoms. The LJ parameters between\ndifferent atom types are calculated using a mixing rule, such as\n\u03c3ij =\n(\u03c3ii +\n\u03c3jj)/2 and\n (Lorentz\u2013Berthelot rules).",
            "cite_spans": [],
            "section": "Calculation of Binding Energy ::: Methods",
            "ref_spans": []
        },
        {
            "text": "The time evolution of the interaction energy is shown in Figure S2, and the time-averaged interaction energy\nover the last 50 ns (50 frames) is shown in Figure\n2g, with standard deviation shown\nby the error bar.",
            "cite_spans": [],
            "section": "Calculation of Binding Energy ::: Methods",
            "ref_spans": [
                {
                    "start": 153,
                    "end": 161,
                    "mention": "Figure\n2",
                    "ref_id": "FIGREF1"
                }
            ]
        }
    ],
    "ref_entries": {
        "FIGREF0": {
            "text": "Figure 1: Structural components of the inhibitors designed: (a)\ninhibitor 1 is composed of\n\u03b11 (residues 21 to 55); (b)\ninhibitor 2 is composed of\n\u03b11, \u03b12, and loose\nchain between \u03b23 and \u03b24\nconnected by a C\u2013C bond between residues 45 and 351\n(residues 21 to 88 and 349 to 357); (c) inhibitor\n3 is composed of \u03b11,\n\u03b12, and \u03b23,\n\u03b24 (residues 21 to 105 and 323 to\n362); (d) inhibitor 4 has the same\ncomposition as inhibitor 3 but different\nlinkage (residues 21 to 95 and 335 to 400); (e) details of\ninhibitor 3 (c), reorganized with residue 323\nconnecting residue 105; (f) details of inhibitor\n3 (d), reorganized with residue 21\nconnecting residue 400. (e-f) Conformation of the\n\u03b1-helices and \u03b2-sheets was maintained with the\nrest adapting to the connection. Coloring scheme: red,\n\u03b1-helices; orange, \u03b2-sheets or other linker\ncomponents; blue, RBD of SARS-CoV-2; gray, other parts of\nACE2; licorice, the initial contacting residues in the\nRBD\u2013ACE2 interface.",
            "type": "figure"
        },
        "FIGREF1": {
            "text": "Figure 2: (a\u2013e) Final conformations of inhibitors\n1, 2, 3,\n4, and control. (f) Averaged\nroot-mean-square deviation for the critical amino acids in\neach inhibitor and for the whole inhibitors when binding\nwith the RBD of SARS-CoV-2. Numbering scale: 1\u20134,\ninhibitors 1\u20134 with RBD;\nC, control system of PD from ACE2 and the RBD of\nSARS-CoV-2. (g) Average interaction energies between the\ncontact residues of inhibitors\n1\u20134 (or ACE2) and\nthe RBD of SARS-CoV-2.",
            "type": "figure"
        }
    },
    "back_matter": [],
    "bib_entries": {
        "BIBREF0": {
            "title": "The Species Severe Acute Respiratory Syndrome-Related\nCoronavirus: Classifying 2019-nCoV and Naming It\nSARS-CoV-2",
            "authors": [],
            "year": 2020,
            "venue": "Nat. Microbiol.",
            "volume": "5",
            "issn": "",
            "pages": "536-544",
            "other_ids": {
                "DOI": [
                    "10.1038/s41564-020-0695-z"
                ]
            }
        },
        "BIBREF1": {
            "title": "Analysis of Therapeutic Targets for SARS-CoV-2 and\nDiscovery of Potential Drugs by Computational\nMethods",
            "authors": [],
            "year": 2020,
            "venue": "Acta Pharm. Sin. B",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.1016/j.apsb.2020.02.008"
                ]
            }
        },
        "BIBREF2": {
            "title": "Fast Identification of Possible Drug Treatment of\nCoronavirus Disease-19 (COVID-19) Through Computational Drug\nRepurposing Study",
            "authors": [],
            "year": null,
            "venue": "ChemRxix",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF3": {
            "title": "Molecular Modeling and Chemical Modification for\nFinding Peptide Inhibitor Against Severe Acute Respiratory\nSyndrome Coronavirus Main Proteinase",
            "authors": [],
            "year": 2005,
            "venue": "Anal. Biochem.",
            "volume": "337",
            "issn": "",
            "pages": "262-270",
            "other_ids": {
                "DOI": [
                    "10.1016/j.ab.2004.10.003"
                ]
            }
        },
        "BIBREF4": {
            "title": "Computational Simulation of Interactions between SARS\nCoronavirus Spike Mutants and Host Species-Specific\nReceptors",
            "authors": [],
            "year": 2007,
            "venue": "Comput. Biol. Chem.",
            "volume": "31",
            "issn": "",
            "pages": "134-137",
            "other_ids": {
                "DOI": [
                    "10.1016/j.compbiolchem.2007.02.006"
                ]
            }
        },
        "BIBREF5": {
            "title": "Broad-Spectrum Non-Toxic Antiviral Nanoparticles with a\nVirucidal Inhibition Mechanism",
            "authors": [],
            "year": 2018,
            "venue": "Nat. Mater.",
            "volume": "17",
            "issn": "",
            "pages": "195-203",
            "other_ids": {
                "DOI": [
                    "10.1038/nmat5053"
                ]
            }
        },
        "BIBREF6": {
            "title": "Modified Cyclodextrins As Broad-Spectrum\nAntivirals",
            "authors": [],
            "year": 2020,
            "venue": "Sci. Adv.",
            "volume": "6",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.1126/sciadv.aax9318"
                ]
            }
        },
        "BIBREF7": {
            "title": "Computational Studies of Micellar and Nanoparticle\nNanomedicines",
            "authors": [],
            "year": 2018,
            "venue": "Chem. Soc. Rev.",
            "volume": "47",
            "issn": "",
            "pages": "3849-3860",
            "other_ids": {
                "DOI": [
                    "10.1039/C8CS00022K"
                ]
            }
        },
        "BIBREF8": {
            "title": "Protein Therapeutics: A Summary and Pharmacological\nClassification",
            "authors": [],
            "year": 2008,
            "venue": "Nat. Rev. Drug Discovery",
            "volume": "7",
            "issn": "",
            "pages": "21-39",
            "other_ids": {
                "DOI": [
                    "10.1038/nrd2399"
                ]
            }
        },
        "BIBREF9": {
            "title": "Designing Inhaled Protein Therapeutics for Topical Lung\nDelivery: What Are the Next Steps?",
            "authors": [],
            "year": 2018,
            "venue": "Expert Opin. Drug Delivery",
            "volume": "15",
            "issn": "",
            "pages": "729-736",
            "other_ids": {
                "DOI": [
                    "10.1080/17425247.2018.1503251"
                ]
            }
        },
        "BIBREF10": {
            "title": "Scalable Molecular Dynamics with NAMD",
            "authors": [],
            "year": 2005,
            "venue": "J. Comput. Chem.",
            "volume": "26",
            "issn": "",
            "pages": "1781-1802",
            "other_ids": {
                "DOI": [
                    "10.1002/jcc.20289"
                ]
            }
        },
        "BIBREF11": {
            "title": "Epidemiological and Clinical Characteristics of 99\nCases of 2019 Novel Coronavirus Pneumonia in Wuhan, China: A\nDescriptive Study",
            "authors": [],
            "year": 2020,
            "venue": "Lancet",
            "volume": "395",
            "issn": "",
            "pages": "507-513",
            "other_ids": {
                "DOI": [
                    "10.1016/S0140-6736(20)30211-7"
                ]
            }
        },
        "BIBREF12": {
            "title": "All-Atom Empirical Potential for Molecular Modeling and\nDynamcis Studies of Proteins",
            "authors": [],
            "year": 1998,
            "venue": "J. Phys. Chem. B",
            "volume": "102",
            "issn": "",
            "pages": "3586-3616",
            "other_ids": {
                "DOI": [
                    "10.1021/jp973084f"
                ]
            }
        },
        "BIBREF13": {
            "title": "Particle Mesh Ewald: An N.log(N) Method for Ewald Sums\nin Large Systems",
            "authors": [],
            "year": 1993,
            "venue": "J. Chem. Phys.",
            "volume": "98",
            "issn": "",
            "pages": "10089-10092",
            "other_ids": {
                "DOI": [
                    "10.1063/1.464397"
                ]
            }
        },
        "BIBREF14": {
            "title": "Clinical Features of Patients Infected with 2019 Novel\nCoronavirus in Wuhan, China",
            "authors": [],
            "year": 2020,
            "venue": "Lancet",
            "volume": "395",
            "issn": "",
            "pages": "497-506",
            "other_ids": {
                "DOI": [
                    "10.1016/S0140-6736(20)30183-5"
                ]
            }
        },
        "BIBREF15": {
            "title": "A Pneumonia Outbreak Associated with a New Coronavirus\nof Probable Bat Origin",
            "authors": [],
            "year": 2020,
            "venue": "Nature",
            "volume": "579",
            "issn": "",
            "pages": "270-273",
            "other_ids": {
                "DOI": [
                    "10.1038/s41586-020-2012-7"
                ]
            }
        },
        "BIBREF16": {
            "title": "Cryo-EM Structure of the 2019-nCoV Spike in the\nPrefusion Conformation",
            "authors": [],
            "year": 2020,
            "venue": "Science",
            "volume": "367",
            "issn": "",
            "pages": "1260-1263",
            "other_ids": {
                "DOI": [
                    "10.1126/science.abb2507"
                ]
            }
        },
        "BIBREF17": {
            "title": "Structure, Function, and Evolution of Coronavirus Spike\nProteins",
            "authors": [],
            "year": 2016,
            "venue": "Annu. Rev. Virol.",
            "volume": "3",
            "issn": "",
            "pages": "237-261",
            "other_ids": {
                "DOI": [
                    "10.1146/annurev-virology-110615-042301"
                ]
            }
        },
        "BIBREF18": {
            "title": "The Coronavirus Spike Protein Is a Class I Virus Fusion\nProtein: Structural and Functional Characterization of the\nFusion Core Complex",
            "authors": [],
            "year": 2003,
            "venue": "J. Virol.",
            "volume": "77",
            "issn": "",
            "pages": "8801-8811",
            "other_ids": {
                "DOI": [
                    "10.1128/JVI.77.16.8801-8811.2003"
                ]
            }
        },
        "BIBREF19": {
            "title": "Receptor Recognition by the Novel Coronavirus from\nWuhan: An Analysis Based on Decade-Long Structural Studies of\nSARS Coronavirus",
            "authors": [],
            "year": 2020,
            "venue": "J. Virol.",
            "volume": "94",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.1128/JVI.00127-20"
                ]
            }
        },
        "BIBREF20": {
            "title": "Structural Basis for the Recognition of the SARS-CoV-2\nby Full-Length Human ACE2",
            "authors": [],
            "year": 2020,
            "venue": "Science",
            "volume": "367",
            "issn": "",
            "pages": "1444-1448",
            "other_ids": {
                "DOI": [
                    "10.1126/science.abb2762"
                ]
            }
        }
    }
}